TY - JOUR
T1 - Clinical development and potential of photothermal and photodynamic therapies for cancer
AU - Li, Xingshu
AU - Lovell, Jonathan F.
AU - Yoon, Juyoung
AU - Chen, Xiaoyuan
N1 - Funding Information:
The work of the authors is supported by the National Research Foundation of Korea (NRF), which is funded by the Korean government Ministry of Science (grant 2012R1A-3A2048814 to J.Y.), the US NIH (grants R01EB017270 and DP5OD017898 to J.F.L.), the US National Science Foundation (grant 1555220 to J.F.L.), and the Intramural Research Program (IRP) of the NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB) (X.C.). The authors would like to thank Dr David Kessel for providing valuable feedback on the manuscript and Tian Guo and Rui Wang for their assistance in formatting the manuscript.
Publisher Copyright:
© 2020, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Light-activated, photosensitizer-based therapies have been established as safe modalities of tumour ablation for numerous cancer indications. Two main approaches are available: photodynamic therapy, which results in localized chemical damage in the target lesions, and photothermal therapy, which results in localized thermal damage. Whereas the administration of photosensitizers is a key component of photodynamic therapy, exogenous photothermal contrast agents are not required for photothermal therapy but can enhance the efficiency and efficacy of treatment. Over the past decades, great strides have been made in the development of phototherapeutic drugs and devices as cancer treatments, but key challenges have restricted their widespread clinical use outside of certain dermatological indications. Improvements in the tumour specificity of photosensitizers, achieved through targeting or localized activation, could provide better outcomes with fewer adverse effects, as could combinations with chemotherapies or immunotherapies. In this Review, we provide an overview of the current clinical progress of phototherapies for cancer and discuss the emerging preclinical bioengineering approaches that have the potential to overcome challenges in this area and thus improve the efficiency and utility of such treatments.
AB - Light-activated, photosensitizer-based therapies have been established as safe modalities of tumour ablation for numerous cancer indications. Two main approaches are available: photodynamic therapy, which results in localized chemical damage in the target lesions, and photothermal therapy, which results in localized thermal damage. Whereas the administration of photosensitizers is a key component of photodynamic therapy, exogenous photothermal contrast agents are not required for photothermal therapy but can enhance the efficiency and efficacy of treatment. Over the past decades, great strides have been made in the development of phototherapeutic drugs and devices as cancer treatments, but key challenges have restricted their widespread clinical use outside of certain dermatological indications. Improvements in the tumour specificity of photosensitizers, achieved through targeting or localized activation, could provide better outcomes with fewer adverse effects, as could combinations with chemotherapies or immunotherapies. In this Review, we provide an overview of the current clinical progress of phototherapies for cancer and discuss the emerging preclinical bioengineering approaches that have the potential to overcome challenges in this area and thus improve the efficiency and utility of such treatments.
UR - http://www.scopus.com/inward/record.url?scp=85088397340&partnerID=8YFLogxK
U2 - 10.1038/s41571-020-0410-2
DO - 10.1038/s41571-020-0410-2
M3 - Review article
C2 - 32699309
AN - SCOPUS:85088397340
SN - 1759-4774
VL - 17
SP - 657
EP - 674
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 11
ER -